Fanconi Anemia clinical trials

Explore recruiting fanconi anemia clinical trials.

Recruiting fanconi anemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fanconi Anemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A: FANCOLEN-I

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

AFAN trial. Phase Ib/II study to investigate the safety and efficacy of Afatinib when administered as therapy in Fanconi anemia patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial.

Netherlands, Belgium, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Fanconi Anemia trials by city

Fanconi Anemia in Toronto Fanconi Anemia in Vancouver Fanconi Anemia in Montreal Fanconi Anemia in Calgary Fanconi Anemia in Edmonton Fanconi Anemia in Ottawa Fanconi Anemia in Winnipeg Fanconi Anemia in Quebec City Fanconi Anemia in Hamilton Fanconi Anemia in Kitchener Fanconi Anemia in London Fanconi Anemia in Halifax Fanconi Anemia in New York Fanconi Anemia in Los Angeles Fanconi Anemia in Chicago Fanconi Anemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease